CSPC Pharmaceutical (HKG:1093) obtained clinical trial approval for JMT203, developed by unit Shanghai JMT-BIO Technology, from the U.S. Food and Drug Administration (FDA), a Tuesday filing with the Hong Kong bourse said.
The drug, which had obtained trial approval from the National Medical Products Administration in June 2023, is currently undergoing trials in China.
The indication for this approval is cancer cachexia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.